L-theanineTHECNANCT02770105
Theanine and Caffeine on Neurophysiology of Attention
A study testing Theanine, Caffeine and Theanine-Caffeine Combination in people with L-theanine, run by Texas Tech University at 1 site in United States.
Trial summary
L-theanine and caffeine are nutritional compounds that are naturally found in tea. Our recent findings using an EEG paradigm are consistent with the findings of others, indicating that intake of L-theanine and caffeine reduce the time needed for a person to differentiate between two visual stimuli and react to only… Read more about this study
- Who is it for?
- Ages 18 to 60 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- L-theanine
- What is being tested?
- Theanine, Caffeine and Theanine-Caffeine Combination
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 9 participants
- Where
- 1 siteUnited States
- Study dates
- May 2016to Jun 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy males*
- Age 18-60 years
Who cannot join
- Gross impairment of vision or hearing that would prevent the participants from recognizing visual stimuli
- Physical, psychiatric or neurological impairment that could affect cognitive or motor functions
- Exposure to toxins or substances that are known to affect visual, auditory, cognitive or motor functions
- Regular intake of medication that could alter visual, auditory, cognitive or motor functions
- History of and / or current alcohol and / or drug abuse
- Disease or condition known to be precipitated or aggravated by tea or coffee
Show all 10Show fewer
- Intake of drugs containing caffeine, other phosphodiesterase inhibitors or adenosine receptor blockers
- Intake of medications which are known to have pharmacological interactions with caffeine
- Participants with contra-indications to undergo fMRI scanning
- Unwilling or unable to discontinue the use of cell phones, smart phones or other electronic devices during the entire study visit.
Trial locations and contacts
1 site in 1 country.
United States1 site
Texas Tech University - Department of Nutritional Sciences
Lubbock, Texas, 79409
About this study
Official title: Neurophysiological Correlates of L-theanine, Caffeine and Their Combination on Improving Selective Attention in a Visual Reaction Time Task: A Functional Magnetic Resonance Imaging (fMRI) Study
L-theanine and caffeine are nutritional compounds that are naturally found in tea. Our recent findings using an EEG paradigm are consistent with the findings of others, indicating that intake of L-theanine and caffeine reduce the time needed for a person to differentiate between two visual stimuli and react to only one stimulus. In order to understand how these compounds give rise to these improvements, the investigators need to study how these compounds are related to various areas of the brain. To achieve this, the investigators plan to scan the brains of nine participants after they take either 1) L-theanine alone, 2) caffeine alone 3) the combination of both L-theanine and caffeine as compared with a placebo (distilled water), to see which has the greatest impact on attention and on regions in the brain that bring about attention.
Read the detailed description
Recruitment: Participants will be recruited through advertisements in social media, electronic and hardcopy noticeboards at Texas Tech University (e.g. Tech Announce, campus bulletin boards), local media (e.g. newspapers), web-based media (e.g. Craig's list) and flyers placed on bulletin boards off campus. Nine participants will be recruited after screening for the following inclusion and exclusion criteria.
Pre-Screening (Telephone): Individuals who express an interest in participating will be contacted by a graduate or an undergraduate research assistant who will administer a structured telephone interview to: 1) provide information related to the requirements of the study, along with potential risks and benefits 2) Screen for eligibility based on specific inclusion and exclusion criteria. All potential subjects will be informed that their responses will remain confidential and that taking part in the screening interview in no way obligates them to participate.
The first 9 participants who meet eligibility criteria will be scheduled for their appointments (at Texas Tech Neuroimaging Institute; TTNI) immediately or within 48 hours of the telephone conversation depending on the discretion of each potential participant. Each participant will be required to complete 5 visits to TTNI, scheduled at least 5 days apart, in order to complete their participation in the study. The first visit will be 45 minutes in length and each of the 4 subsequent visits will be 90 minutes in length. The participants will be given the right to withdraw from the study at any point. In the event that a screened and included participant should discontinue the study prematurely, additional subjects will be recruited to maintain study total at 9 completers. Since the study is a cross-over design, all participants will be exposed to all experimental conditions (i.e. theanine, caffeine, TC and distilled water) in a random order.
Measurements:
- Recognition Visual Reaction Time (RVRT) Task: Participants will be instructed on the importance of accuracy in performing the RVRT task in advance. A blue-colored background will be presented. Participants will be requested to press a button on a computer keyboard (during practice sessions) and on a fiber optic hand-held device during active testing sessions (in the fMRI scanner) using the index finger of the dominant hand in response to a white flash lasting for 30ms (target stimulus) as quickly as possible, while ignoring a red colored flash lasting for 30ms (distractor stimulus). During each run, 20±2 stimuli of each category of stimuli will be presented and the inter-stimulus interval will be jittered to 5000ms±3000ms. Time taken to respond to target stimuli will be recorded as RVRT. Omissions and responses to distractor stimuli (errors) will also be recorded.
- Scanning paradigm: Each scanning session will be scheduled for 20 minutes, comprised of 3 runs of fMRI scans while the participants are performing the RVRT tasks displayed on an LCD screen and projected via a mirror attached to the head coil of the fMRI machine (each run lasting for 4 minutes) followed by a structural (T1-weighted) scan lasting for 5 minutes.
Data Collection Protocol: All recruited participants will be scheduled for 5 visits at the TTNI within 48 hours of receipt and subsequent evaluation of the prescreening material for inclusion and exclusion criteria. Participants will be reminded of the visits via email / telephone (per their stated preference) at both 1 week and again 1 day prior to each visit. The visits will be scheduled at least 5 days apart.
- First Visit: Prescreening, Consent and Training:
- The study will be explained thoroughly to reinforce prior explanations and ensure full understanding.
- Participants will be screened again to verify the inclusion and exclusion criteria by re-administering the screening questionnaire and MRI safety sheet by a member of the BMTR lab.
- Informed written consent will be obtained.
- A participant number will be assigned, that identifies the order of administration of the four substances (i.e. theanine, caffeine, TC and placebo) during the subsequent visits. This order will be determined using a random number generator.
- Each participant will be provided with a solution of 160mg of caffeine dissolved in 200ml of distilled water in a disposable, clean, opaque, plastic cup to be consumed completely within 1 minute, in order to train the participants to consume required substances during the subsequent visits and to ensure that the participants can tolerate the mildly bitter taste of the substances.
- In order to acclimate the participants to the RVRT task they will be performing in the MRI scanner during their subsequent visits, each participant will perform a training session where they will perform the RVRT task in three 5 min sessions, separated by 60 second rest intervals using a laptop computer (under the supervision of a graduate / undergraduate research assistants).
- Each participant will be reminded of the subsequent visits and the importance of adherence to the preparation guidelines.
- Preparation and Administration of Substances: L-theanine and caffeine will be purchased in purified powder form from a registered supplier. Both substances will be stored in air-tight packing prior to preparation for administration according to manufacturer's recommendations. All solutions will be prepared for administration maintaining the highest possible standards of hygiene. Each solution of L-theanine will be made by dissolving 200mg of theanine powder in 200ml of distilled water. Each solution of caffeine will be made by dissolving 160mg of caffeine powder. Both L-theanine and caffeine powder (200mg and 160mg respectively) will be dissolved in a 200ml aliquot of distilled water to form each solution of TC. Two-hundred milliliters of distilled water will be used as the placebo. Each solution will be prepared within 4 hours of scheduled time of administration and stored in a disposable, clean, opaque, cup with a lid. The participants will be instructed to consume the solution completely upon administration.
- Preparation of participants for the Second, Third, Fourth and Fifth Visits: All recruited participants will be instructed to strictly adhere to the following guidelines prior to the 2nd, 3rd, 4th and 5th visits in order to minimize confounding of the results.
- Avoid consumption of alcohol within 48 hours prior to the test
- Avoid smoking 12 hours prior to the test
- Sleep for at least 6 hours on the day prior to the test dates
- Avoid consumption of tea, coffee or foods / beverages containing caffeine within 12 hours prior to the test.
- Second, Third, Fourth and Fifth Visits: Administration of Substances and MRI Scanning:
- Participants will be briefly reminded of the purpose of the study.
- Adherence to the preparation guidelines will be assessed. Should a participant indicate non-adherence to preparation guidelines they will be discontinued from the study.
- The solution (containing the appropriate substance / combination of substances) to be administered to each participant during the visit will be provided in a disposable, clean, cup to be consumed within 1 minute.
- A questionnaire regarding the taste and characteristics of the solution will be administered.
- Each participant will be given a verbal review of the RVRT task and will be allowed to practice the RVRT task on a laptop computer for 5 minutes.
- Each participant will be allowed to relax, seated in a comfortable chair, until 60 minutes elapses from the time of administration of the solution (to allow time for the actions of L-theanine and caffeine on the brain to reach the maximum levels).
- Combined functional and structural MRI scans will be performed while the participants engage in the RVRT tasks.
- Visual analogue scales (100mm lines with the extremes of the measured parameter listed at each end; the participant rates the measured parameter by making a vertical mark on the line) will be administered to measure the perceived improvement / deterioration of RVRT and perceived improvement / deterioration of accuracy in the tasks
- At the end of the 5th visit, each participant will be debriefed.
Analysis: RVRT will be compared across the four conditions (theanine, caffeine, TC and placebo) constructing a repeated measures analysis of variance (ANOVA) model using the R-statistical software. Subsequently, pair-wise comparisons of RVRT will be performed between the four conditions, maintaining the family-wise error rate at 0.05. Following sequence of operations will be conducted on the fMRI data using the FMRIB software library (FSL): visual examination, distortion correction, motion correction, slice timing correction, spatial smoothing and statistical analysis. BOLD responses will be compared across the four conditions by constructing ANOVA models at a whole brain level as well as in the regions of anterior cingulate cortex and antero-medial prefrontal cortex. Pair-wise comparisons of BOLD responses will also be conducted between the conditions. RVRT, omissions and errors will be included as covariates in fMRI analysis.
- Conditions
- L-theanine
- Being tested
- Theanine, Caffeine, Theanine-Caffeine Combination, Placebo
- Keywords
- L-theanine, caffeine, selective attention, fMRI, RVRT
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TheanineOther
Oral administration of 200mg of L-theanine powder dissolved in 200ml of distilled water
CaffeineOther
Oral administration of 160mg of anhydrous caffeine powder dissolved in 200ml of distilled water
Theanine-Caffeine CombinationOther
Oral administration of 200mg of L-theanine and 160mg of anhydrous caffeine powder, dissolved in 200ml of distilled water
PlaceboOther
Oral administration of 200ml of distilled water
What is being measured
The primary outcome is the main question the study is designed to answer.
Differences between fMRI blood oxygen level dependent (BOLD) responses of the brain recorded following administration of each substance and the placebo
Theanine, caffeine, theanine-caffeine combination and distilled water (placebo) will be administered on 4 separate days (at least 5 days apart) in a random order. Functional MRI scans will be performed 60 minutes after each administration. Primary outcome measure will be the difference in fMRI BOLD responses obtained for each substance and the placebo.
Measured: Sixty minutes after administration of each of theanine, caffeine, theanine-caffeine combination and placebo
Secondary outcomes (3)
Differences between mean recognition visual reaction times recorded following administration of each substance and the placebo
Theanine, caffeine, theanine-caffeine combination and distilled water (placebo) will be administered on 4 separate days (at least 5 days apart) in a random order. Functional MRI scans will be performed 60 minutes after each administration. A secondary outcome measure will be the difference in mean recognition visual reaction time task obtained for each substance and the placebo, when the subjects perform the task in the fMRI scanner.
Measured: Sixty minutes after administration of each of theanine, caffeine, theanine-caffeine combination and placebo
Differences between proportion of errors caused while performing the recognition visual reaction time task following administration of each substance and the placebo
Theanine, caffeine, theanine-caffeine combination and distilled water (placebo) will be administered on 4 separate days (at least 5 days apart) in a random order. Functional MRI scans will be performed 60 minutes after each administration. A secondary outcome measure will be the difference in proportion of errors caused while performing the recognition visual reaction time task in the fMRI scanner after each substance and the placebo.
Measured: Sixty minutes after administration of each of theanine, caffeine, theanine-caffeine combination and placebo
Differences between proportion of omissions caused while performing the recognition visual reaction time task following administration of each substance and the placebo
Theanine, caffeine, theanine-caffeine combination and distilled water (placebo) will be administered on 4 separate days (at least 5 days apart) in a random order. Functional MRI scans will be performed 60 minutes after each administration. A secondary outcome measure will be the difference in proportion of omissions caused while performing the recognition visual reaction time task in the fMRI scanner after each substance and the placebo.
Measured: Sixty minutes after administration of each of theanine, caffeine, theanine-caffeine combination and placebo
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 May 2016 (estimated)
- Study startMay 2016
- Primary completionJun 2016
- Study completionJun 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for L-theanineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 9 participants (actual)
Sponsor and investigators
- Lead sponsor
- Texas Tech University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Martin Binks, PhD, Principal investigator, Texas Tech University - Department of Nutritional Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02770105
- Sponsor's protocol ID
- TTUIRB505445
- Acronym
- THECNA
- Status last verified
- May 2016
- First submitted
- 6 May 2016
- Last updated
- 2 Sep 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Kahathuduwa CN, Dassanayake TL, Amarakoon AMT, Weerasinghe VS. Acute effects of theanine, caffeine and theanine-caffeine combination on attention. Nutr Neurosci. 2017 Jul;20(6):369-377. doi: 10.1080/1028415X.2016.1144845. Epub 2016 Feb 12.
PubMed 26869148Weerasinghe V, Kahathuduwa C, Amarakoon T, Dassanayake T. Synergistic Effect of Theanine and Caffeine on Visual Reaction Time, Evoked Potentials and Cognitive Event Related Potentials. Journal of Clinical Neurophysiology. 2015; 32(4): S396.
Camfield DA, Stough C, Farrimond J, Scholey AB. Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis. Nutr Rev. 2014 Aug;72(8):507-22. doi: 10.1111/nure.12120. Epub 2014 Jun 19.
PubMed 24946991
Study at a glance
From the registry record, last updated by the sponsor on 2 Sep 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Neurophysiological Correlates of L-theanine, Caffeine and Their Combination on Improving Selective Attention in a Visual Reaction Time Task: A Functional Magnetic Resonance Imaging (fMRI) Study
- ClinicalTrials.gov ID
- NCT02770105
- Acronym / sponsor ID
- THECNA / TTUIRB505445
- Conditions
- L-theanine
- Keywords
- L-theanine, caffeine, selective attention, fMRI, RVRT
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 9 participants (actual)
- Lead sponsor
- Texas Tech UniversityUniversity, hospital or other
- Study start
- May 2016
- Primary completion
- Jun 2016 (actual)
- Study completion
- Jun 2016 (actual)
- First posted
- 12 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
L-theanine and caffeine are nutritional compounds that are naturally found in tea. Our recent findings using an EEG paradigm are consistent with the findings of others, indicating that intake of L-theanine and caffeine reduce the time needed for a person to differentiate between two visual stimuli and react to only one stimulus. In order to understand how these compounds give rise to these improvements, the investigators need to study how these compounds are related to various areas of the brain. To achieve this, the investigators plan to scan the brains of nine participants after they take either 1) L-theanine alone, 2) caffeine alone 3) the combination of both L-theanine and caffeine as compared with a placebo (distilled water), to see which has the greatest impact on attention and on regions in the brain that bring about attention.
Detailed description
Recruitment: Participants will be recruited through advertisements in social media, electronic and hardcopy noticeboards at Texas Tech University (e.g. Tech Announce, campus bulletin boards), local media (e.g. newspapers), web-based media (e.g. Craig's list) and flyers placed on bulletin boards off campus. Nine participants will be recruited after screening for the following inclusion and exclusion criteria.
Pre-Screening (Telephone): Individuals who express an interest in participating will be contacted by a graduate or an undergraduate research assistant who will administer a structured telephone interview to: 1) provide information related to the requirements of the study, along with potential risks and benefits 2) Screen for eligibility based on specific inclusion and exclusion criteria. All potential subjects will be informed that their responses will remain confidential and that taking part in the screening interview in no way obligates them to participate.
The first 9 participants who meet eligibility criteria will be scheduled for their appointments (at Texas Tech Neuroimaging Institute; TTNI) immediately or within 48 hours of the telephone conversation depending on the discretion of each potential participant. Each participant will be required to complete 5 visits to TTNI, scheduled at least 5 days apart, in order to complete their participation in the study. The first visit will be 45 minutes in length and each of the 4 subsequent visits will be 90 minutes in length. The participants will be given the right to withdraw from the study at any point. In the event that a screened and included participant should discontinue the study prematurely, additional subjects will be recruited to maintain study total at 9 completers. Since the study is a cross-over design, all participants will be exposed to all experimental conditions (i.e. theanine, caffeine, TC and distilled water) in a random order.
Measurements:
- Recognition Visual Reaction Time (RVRT) Task: Participants will be instructed on the importance of accuracy in performing the RVRT task in advance. A blue-colored background will be presented. Participants will be requested to press a button on a computer keyboard (during practice sessions) and on a fiber optic hand-held device during active testing sessions (in the fMRI scanner) using the index finger of the dominant hand in response to a white flash lasting for 30ms (target stimulus) as quickly as possible, while ignoring a red colored flash lasting for 30ms (distractor stimulus). During each run, 20±2 stimuli of each category of stimuli will be presented and the inter-stimulus interval will be jittered to 5000ms±3000ms. Time taken to respond to target stimuli will be recorded as RVRT. Omissions and responses to distractor stimuli (errors) will also be recorded.
- Scanning paradigm: Each scanning session will be scheduled for 20 minutes, comprised of 3 runs of fMRI scans while the participants are performing the RVRT tasks displayed on an LCD screen and projected via a mirror attached to the head coil of the fMRI machine (each run lasting for 4 minutes) followed by a structural (T1-weighted) scan lasting for 5 minutes.
Data Collection Protocol: All recruited participants will be scheduled for 5 visits at the TTNI within 48 hours of receipt and subsequent evaluation of the prescreening material for inclusion and exclusion criteria. Participants will be reminded of the visits via email / telephone (per their stated preference) at both 1 week and again 1 day prior to each visit. The visits will be scheduled at least 5 days apart.
- First Visit: Prescreening, Consent and Training:
- The study will be explained thoroughly to reinforce prior explanations and ensure full understanding.
- Participants will be screened again to verify the inclusion and exclusion criteria by re-administering the screening questionnaire and MRI safety sheet by a member of the BMTR lab.
- Informed written consent will be obtained.
- A participant number will be assigned, that identifies the order of administration of the four substances (i.e. theanine, caffeine, TC and placebo) during the subsequent visits. This order will be determined using a random number generator.
- Each participant will be provided with a solution of 160mg of caffeine dissolved in 200ml of distilled water in a disposable, clean, opaque, plastic cup to be consumed completely within 1 minute, in order to train the participants to consume required substances during the subsequent visits and to ensure that the participants can tolerate the mildly bitter taste of the substances.
- In order to acclimate the participants to the RVRT task they will be performing in the MRI scanner during their subsequent visits, each participant will perform a training session where they will perform the RVRT task in three 5 min sessions, separated by 60 second rest intervals using a laptop computer (under the supervision of a graduate / undergraduate research assistants).
- Each participant will be reminded of the subsequent visits and the importance of adherence to the preparation guidelines.
- Preparation and Administration of Substances: L-theanine and caffeine will be purchased in purified powder form from a registered supplier. Both substances will be stored in air-tight packing prior to preparation for administration according to manufacturer's recommendations. All solutions will be prepared for administration maintaining the highest possible standards of hygiene. Each solution of L-theanine will be made by dissolving 200mg of theanine powder in 200ml of distilled water. Each solution of caffeine will be made by dissolving 160mg of caffeine powder. Both L-theanine and caffeine powder (200mg and 160mg respectively) will be dissolved in a 200ml aliquot of distilled water to form each solution of TC. Two-hundred milliliters of distilled water will be used as the placebo. Each solution will be prepared within 4 hours of scheduled time of administration and stored in a disposable, clean, opaque, cup with a lid. The participants will be instructed to consume the solution completely upon administration.
- Preparation of participants for the Second, Third, Fourth and Fifth Visits: All recruited participants will be instructed to strictly adhere to the following guidelines prior to the 2nd, 3rd, 4th and 5th visits in order to minimize confounding of the results.
- Avoid consumption of alcohol within 48 hours prior to the test
- Avoid smoking 12 hours prior to the test
- Sleep for at least 6 hours on the day prior to the test dates
- Avoid consumption of tea, coffee or foods / beverages containing caffeine within 12 hours prior to the test.
- Second, Third, Fourth and Fifth Visits: Administration of Substances and MRI Scanning:
- Participants will be briefly reminded of the purpose of the study.
- Adherence to the preparation guidelines will be assessed. Should a participant indicate non-adherence to preparation guidelines they will be discontinued from the study.
- The solution (containing the appropriate substance / combination of substances) to be administered to each participant during the visit will be provided in a disposable, clean, cup to be consumed within 1 minute.
- A questionnaire regarding the taste and characteristics of the solution will be administered.
- Each participant will be given a verbal review of the RVRT task and will be allowed to practice the RVRT task on a laptop computer for 5 minutes.
- Each participant will be allowed to relax, seated in a comfortable chair, until 60 minutes elapses from the time of administration of the solution (to allow time for the actions of L-theanine and caffeine on the brain to reach the maximum levels).
- Combined functional and structural MRI scans will be performed while the participants engage in the RVRT tasks.
- Visual analogue scales (100mm lines with the extremes of the measured parameter listed at each end; the participant rates the measured parameter by making a vertical mark on the line) will be administered to measure the perceived improvement / deterioration of RVRT and perceived improvement / deterioration of accuracy in the tasks
- At the end of the 5th visit, each participant will be debriefed.
Analysis: RVRT will be compared across the four conditions (theanine, caffeine, TC and placebo) constructing a repeated measures analysis of variance (ANOVA) model using the R-statistical software. Subsequently, pair-wise comparisons of RVRT will be performed between the four conditions, maintaining the family-wise error rate at 0.05. Following sequence of operations will be conducted on the fMRI data using the FMRIB software library (FSL): visual examination, distortion correction, motion correction, slice timing correction, spatial smoothing and statistical analysis. BOLD responses will be compared across the four conditions by constructing ANOVA models at a whole brain level as well as in the regions of anterior cingulate cortex and antero-medial prefrontal cortex. Pair-wise comparisons of BOLD responses will also be conducted between the conditions. RVRT, omissions and errors will be included as covariates in fMRI analysis.
Study design
- Intervention model
- Crossover
- Masking
- Single blind (participant)
Who may qualify
- Ages
- 18 to 60 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Healthy males*
- Age 18-60 years
Key exclusion criteria (10 listed)
- Gross impairment of vision or hearing that would prevent the participants from recognizing visual stimuli
- Physical, psychiatric or neurological impairment that could affect cognitive or motor functions
- Exposure to toxins or substances that are known to affect visual, auditory, cognitive or motor functions
- Regular intake of medication that could alter visual, auditory, cognitive or motor functions
- History of and / or current alcohol and / or drug abuse
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TheanineOral administration of 200mg of L-theanine powder dissolved in 200ml of distilled water | Other | – |
| CaffeineOral administration of 160mg of anhydrous caffeine powder dissolved in 200ml of distilled water | Other | – |
| Theanine-Caffeine CombinationOral administration of 200mg of L-theanine and 160mg of anhydrous caffeine powder, dissolved in 200ml of distilled water | Other | – |
| PlaceboOral administration of 200ml of distilled water | Other | – |
Primary outcome
Differences between fMRI blood oxygen level dependent (BOLD) responses of the brain recorded following administration of each substance and the placebo
Time frame: Sixty minutes after administration of each of theanine, caffeine, theanine-caffeine combination and placebo
Theanine, caffeine, theanine-caffeine combination and distilled water (placebo) will be administered on 4 separate days (at least 5 days apart) in a random order. Functional MRI scans will be performed 60 minutes after each administration. Primary outcome measure will be the difference in fMRI BOLD responses obtained for each substance and the placebo.
3 secondary outcomes
Differences between mean recognition visual reaction times recorded following administration of each substance and the placebo
Time frame: Sixty minutes after administration of each of theanine, caffeine, theanine-caffeine combination and placebo
Differences between proportion of errors caused while performing the recognition visual reaction time task following administration of each substance and the placebo
Time frame: Sixty minutes after administration of each of theanine, caffeine, theanine-caffeine combination and placebo
Differences between proportion of omissions caused while performing the recognition visual reaction time task following administration of each substance and the placebo
Time frame: Sixty minutes after administration of each of theanine, caffeine, theanine-caffeine combination and placebo
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2016.
- Background: PubMed 26869148Kahathuduwa CN, Dassanayake TL, Amarakoon AMT, Weerasinghe VS. Acute effects of theanine, caffeine and theanine-caffeine combination on attention. Nutr Neurosci. 2017 Jul;20(6):369-377. doi: 10.1080/1028415X.2016.1144845. Epub 2016 Feb 12.
- BackgroundWeerasinghe V, Kahathuduwa C, Amarakoon T, Dassanayake T. Synergistic Effect of Theanine and Caffeine on Visual Reaction Time, Evoked Potentials and Cognitive Event Related Potentials. Journal of Clinical Neurophysiology. 2015; 32(4): S396.
- Background: PubMed 24946991Camfield DA, Stough C, Farrimond J, Scholey AB. Acute effects of tea constituents L-theanine, caffeine, and epigallocatechin gallate on cognitive function and mood: a systematic review and meta-analysis. Nutr Rev. 2014 Aug;72(8):507-22. doi: 10.1111/nure.12120. Epub 2014 Jun 19.
- Individual participant dataSharing planned: No
Related trials for L-theanine
Recruiting
L-THEANINE AND MEDITERRANEAN DIET ON RBD, GI FUNCTION, AND INFLAMMATION IN PARKINSON'S DISEASE
Parkinson Disease (PD)
RecruitingEarly Phase 1
L-Theanine to Support Relaxation and Mood for Cancer Patients in Surveillance
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Recruiting
The Effects of Resistance Training and a Plant-Based Supplement on Perimenopausal Symptoms and Muscle Health.
Perimenopause, Menopause
Recruiting
Evaluation of the Impact of a Nutritional Formulation on Cognitive Performance Following Stress Exposure.
Cognitive Assessment, Working Memory
Recruiting
Effects of Chamomile With L-theanine Beverage Among Young Women Experiencing Primary Dysmenorrhea
Primary Dysmenorrhea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Martin Binks, PhD principal investigator
Texas Tech University - Department of Nutritional Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Theanine, Caffeine and Theanine-Caffeine Combination in people with L-theanine, run by Texas Tech University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Differences between fMRI blood oxygen level dependent (BOLD) responses of the brain recorded following administration of each substance and the placebo (time frame: Sixty minutes after administration of each of theanine, caffeine, theanine-caffeine combination and placebo). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02770105, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2016.